Anti-CD38 monoclonal antibody that targets clonal plasma cells and mediates ADCC, CDC, apoptosis, and immunomodulatory effects.
Human IgG1κ anti‑CD38 monoclonal antibody that binds CD38 on clonal plasma cells, inducing direct cell death and immune‑mediated killing via ADCC, ADCP, and CDC; also depletes CD38+ immunosuppressive cells, contributing to antitumor immune modulation.
YES
DIRECT
The antibody binds CD38 on target cells and triggers Fc-mediated ADCC (NK cells), ADCP (macrophages), and complement-dependent cytotoxicity (CDC), and can also induce direct apoptosis of CD38+ cells.
Allogeneic cord blood–derived natural killer cells engineered with a TROP2-specific CAR and an IL-15 transgene to provide targeted NK cytotoxicity against TROP2-positive tumor cells and enhance NK survival and persistence.
Allogeneic cord blood–derived NK cells engineered with a TROP2-specific chimeric antigen receptor to direct antigen-specific NK cytotoxicity against TROP2-positive tumor cells; co-expression of IL-15 supports NK activation, survival, proliferation, and persistence in vivo.
NO
INDIRECT
TROP2-CAR-NK cells specifically recognize TROP2, not human IgG1 Fc. They kill TROP2-positive cells via NK degranulation (perforin/granzyme) and cytokine-mediated cytotoxicity; cells bearing IgG1 Fc are not targeted.
Investigational anticancer immunotherapy drug administered intravenously; specific molecular target/mechanism not disclosed in the registry entry.
Bispecific antibody that binds CEA (CEACAM5) on tumor cells and 4-1BB (CD137) on activated T cells and NK cells, crosslinking them to deliver localized 4-1BB costimulation in the tumor microenvironment. This enhances cytotoxic T-cell activity and leads to lysis of CEA-expressing tumor cells; may also interfere with CEA-mediated signaling.
YES
DIRECT
BGB-B167 binds CEA on tumor cells and 4-1BB on T/NK cells, providing localized 4-1BB costimulation that activates cytotoxic lymphocytes to lyse CEA-expressing cells (perforin/granzyme-mediated killing).
Investigational anticancer immunotherapy drug administered intravenously; specific molecular target/mechanism not disclosed in the registry entry.
Bispecific antibody that binds CEA (CEACAM5) on tumor cells and 4-1BB (CD137) on activated T cells and NK cells, crosslinking them to deliver localized 4-1BB costimulation in the tumor microenvironment. This enhances cytotoxic T-cell activity and leads to lysis of CEA-expressing tumor cells; may also interfere with CEA-mediated signaling.
NO
INDIRECT
BGB-B167 crosslinks CEA on tumor cells with 4-1BB on T/NK cells to provide localized 4-1BB costimulation, boosting T-cell cytotoxicity against CEA+ tumor cells. 4-1BB–expressing immune cells are not killed.